336 related articles for article (PubMed ID: 23478488)
1. [Permanent implant prostate cancer brachytherapy: 2013 state-of-the art].
Cosset JM; Hannoun-Lévi JM; Peiffert D; Delannes M; Pommier P; Pierrat N; Nickers P; Thomas L; Chauveinc L
Cancer Radiother; 2013 Apr; 17(2):111-7. PubMed ID: 23478488
[TBL] [Abstract][Full Text] [Related]
2. [Permanent implant prostate cancer brachytherapy].
Cosset JM; Flam T; Thiounn N; Pontvert D; Pierrat N; Vallancien G; Chauveinc L
Cancer Radiother; 2008 Nov; 12(6-7):503-11. PubMed ID: 18829365
[TBL] [Abstract][Full Text] [Related]
3. [Intraoperative and post-implant dosimetry in patients treated with permanent prostate implant brachytherapy].
Herein A; Ágoston P; Szabó Z; Jorgo K; Markgruber B; Pesznyák C; Polgár C; Major T
Magy Onkol; 2015 Jun; 59(2):148-53. PubMed ID: 26035163
[TBL] [Abstract][Full Text] [Related]
4. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
5. Seed displacements after permanent brachytherapy for prostate cancer in dependence on the prostate level.
Pinkawa M; Gagel B; Asadpour B; Piroth MD; Klotz J; Borchers H; Jakse G; Eble MJ
Strahlenther Onkol; 2008 Oct; 184(10):520-5. PubMed ID: 19016041
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the relationship between prescribed dose and dosimetric advantage of real-time intraoperatively built custom-linked seeds in iodine-125 prostate brachytherapy.
Hirose K; Aoki M; Sato M; Akimoto H; Hashimoto Y; Imai A; Kamimura N; Kawaguchi H; Hatayama Y; Fujioka I; Tanaka M; Ohyama C; Takai Y
Radiat Oncol; 2017 Dec; 12(1):192. PubMed ID: 29191234
[TBL] [Abstract][Full Text] [Related]
7. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
8. [Which modality for prostate brachytherapy?].
Bossi A
Cancer Radiother; 2010 Oct; 14(6-7):488-92. PubMed ID: 20724190
[TBL] [Abstract][Full Text] [Related]
9. Focal or whole-gland salvage prostate brachytherapy with iodine seeds with or without a rectal spacer for postradiotherapy local failure: How best to spare the rectum?
Guimas V; Quivrin M; Bertaut A; Martin E; Chambade D; Maingon P; Mazoyer F; Cormier L; Créhange G
Brachytherapy; 2016; 15(4):406-411. PubMed ID: 27317949
[TBL] [Abstract][Full Text] [Related]
10. [Permanent implant brachytherapy for early, organ-confined prostate cancer].
Agoston P; Major T; Fröhlich G; Baricza K; Szabó Z; Lövey J; Varjas G; Kásler M; Fodor J; Polgár C
Magy Onkol; 2011 Sep; 55(3):170-7. PubMed ID: 21918742
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
12. Minimizing the number of implantation needles for prostate (125)I brachytherapy: an investigation of possibilities and implications.
Steggerda MJ; van der Poel HG; Moonen LM
Brachytherapy; 2010; 9(4):319-27. PubMed ID: 20691644
[TBL] [Abstract][Full Text] [Related]
13. Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study.
Ohashi T; Yorozu A; Saito S; Tanaka N; Katayama N; Kojima S; Maruo S; Kikuchi T; Dokiya T; Fukushima M; Yamanaka H
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):141-9. PubMed ID: 26279031
[TBL] [Abstract][Full Text] [Related]
14. [Brachytherapy for prostate cancer: old concept, new techniques].
Cosset JM; Flam T; Thiounn N; Rosenwald JC; Pontvert D; Timbert M; Solignac S; Chauveinc L
Bull Cancer; 2006 Aug; 93(8):761-6. PubMed ID: 16935780
[TBL] [Abstract][Full Text] [Related]
15. Loose versus stranded seeds in permanent prostate brachytherapy: dosimetric comparison of intraoperative plans.
Major T; Agoston P; Fröhlich G; Baricza K; Szabo Z; Jorgo K; Herein A; Polgar C
Phys Med; 2014 Dec; 30(8):909-13. PubMed ID: 25175151
[TBL] [Abstract][Full Text] [Related]
16. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
17. The technique of 125I permanent implants.
Maurer U; Eble MJ
Front Radiat Ther Oncol; 2002; 36():159-65. PubMed ID: 11842746
[No Abstract] [Full Text] [Related]
18. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
Albertsen PC
J Urol; 2005 Nov; 174(5):1969-70. PubMed ID: 16217368
[No Abstract] [Full Text] [Related]
19. The role of brachytherapy in the definitive management of prostate cancer.
Crook J
Cancer Radiother; 2011 Jun; 15(3):230-7. PubMed ID: 21514199
[TBL] [Abstract][Full Text] [Related]
20. Treatment technique evolution and dosimetry trends over seven years of low dose rate prostate brachytherapy at an Australian institution.
Rutten TP; Lawson JM; Marcu LG
Phys Med; 2013 Nov; 29(6):662-9. PubMed ID: 22975428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
